Table 52Strength of evidence for rFVIIa use in prostatectomy

Outcome of InterestNumber of StudiesNumber of SubjectsDomains Pertaining to Strength of EvidenceEstimated Magnitude of EffectEffect of rFVIIa DosageOverall Strength of Evidence Grade
rFVIIaUsual CareDomains Pertaining to Risk of BiasConsistencyDirectnessPrecision
DesignQualityOverall Risk
Mortality (10 day)11412412RCTFairMediumUnknownDirectImpreciseUnknownUnknownInsufficient
Thromboembolic Events11412412RCTFairMediumUnknownDirectImpreciseUnknownUnknownInsufficient
Units of RBCs Transfused11412412RCTFairMediumUnknownIndirectImpreciseFavors rFVIIaYesInsufficient
OR Time11412412RCTFairMediumUnknownIndirectImpreciseFavors rFVIIaNoInsufficient

RCT=randomized controlled trial; RBCs=red blood cells; OR=operating room. See Tables 4 to 7 for definitions of study quality and strength of evidence domains and designations.

From: Results

Cover of Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care
Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care [Internet].
Comparative Effectiveness Reviews, No. 21.
Yank V, Tuohy CV, Logan AC, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.